REFERENCES
- Sanders WE. New infective problems with old Gram-positive pathogens: setting the stage. Eur J Clin Microbiol Infect Dis 1995; 14 (suppl. 1): 1-2.
- Shason DC. Staphylococcal infections in hospital. Br J Hosp Med 1986; May: 312-320.
- Daschner FD, Kropec A. Glycopeptides in the treatment of staphylococcal infections. Eur J Clin Microbiol Infect Dis 1995; 14 (suppl. 1): 12-17.
- Dalhoff A, Petersen U, Endermann R. In vitro activity of Bay 12-8039, a new 8-methoxyquinolone. Chemotherapy 1996; 42: 410–425.
- Bauernfeind A. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J Antimicrob Chemother 1997; 40: 639–651.
- Woodcock JM, Andrews JM, Boswell FJ, Brenwald NP, Wise R. In vitro activity of Bay 12-8039, a new fluo-rquinolone. Antimicrob Agents Chemother 1997; 41: 101–106.
- Sanders CC, Sanders WE Jr, Thomson KS. Fluoroquinolone resistance in staphylococci: new challenges. Eur J Clin Microbiol Infect Dis 1995; 14 (suppl. 1): 6-11.
- Shah PM. The role of quinolones in staphylococcal infection. J Chemother 1989; 4: 253–256.
- Moody JA, Gerding DN, Peterson LR. Evaluation of ciprofloxacin's synergism with other agents by multiple in-vitro methods. Am J Med 1987; 82 (suppl. 4A): 44-54.
- Roder BL, Gutschik E. In vitro activity of ciprofloxacin with either fusidic acid or rifampicin against Staphylococcus aureus. J Antimicrob Chemother 1989; 23: 347–352.
- Fass RJ, Helsel VL. In vitro antistaphylococcal activity of pefloxacin alone and in combination with other antistaphy-lococcal drugs. Antimicrob Agents Chemother 1987; 31: 1457–1460.
- Smith JT, Lewin CS. Chemistry and mechanism of action of the quinolone antibacterials. In: The quinolones. Andriole VT ed, Academic Press, London, 1989: 62-82.